Form 4: Provectus Biopharmaceuticals CEO Edward Pershing Reports Conversion of Promissory Note into Preferred Stock

CEO Edward Pershing reports the conversion of an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

Summary

• On August 3, 2024, Edward Pershing, CEO of Provectus Biopharmaceuticals, reported a transaction involving the conversion of an 8% unsecured convertible promissory note into 28,320 shares of Series D-1 Convertible Preferred Stock.
• The conversion occurred at a price of $2.862 per share.
• Pershing directly owns 1,442,972 shares of common stock and 1,625,000 shares of Series D-1 Convertible Preferred Stock following the reported transactions.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock and will automatically convert on June 20, 2026, unless converted earlier.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to a pre-existing agreement. The conversion of debt to equity can be seen as a slightly positive sign, but it's not a major event.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a conversion of debt into equity, which can be seen as a positive sign of confidence in the company's future.

Stakeholder Impact

• The conversion of the promissory note into preferred stock could have a minor dilutive effect on existing shareholders, depending on the subsequent conversion of the preferred stock into common stock.

Key Dates